CN104120093B - Bifidobacterium longum and application thereof, and functional food composition and preparation method thereof - Google Patents
Bifidobacterium longum and application thereof, and functional food composition and preparation method thereof Download PDFInfo
- Publication number
- CN104120093B CN104120093B CN201310149307.3A CN201310149307A CN104120093B CN 104120093 B CN104120093 B CN 104120093B CN 201310149307 A CN201310149307 A CN 201310149307A CN 104120093 B CN104120093 B CN 104120093B
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium longum
- thalline
- functional food
- cell
- food composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241001608472 Bifidobacterium longum Species 0.000 title claims abstract description 63
- 229940009291 bifidobacterium longum Drugs 0.000 title claims abstract description 63
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 235000013376 functional food Nutrition 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 32
- 230000000694 effects Effects 0.000 claims abstract description 22
- 235000013305 food Nutrition 0.000 claims abstract description 13
- 230000007365 immunoregulation Effects 0.000 claims abstract description 13
- 241000894006 Bacteria Species 0.000 claims description 53
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 35
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 5
- 238000004321 preservation Methods 0.000 abstract 1
- 239000000725 suspension Substances 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 18
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 14
- 239000007788 liquid Substances 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 11
- 210000000822 natural killer cell Anatomy 0.000 description 11
- 241000186016 Bifidobacterium bifidum Species 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 210000004988 splenocyte Anatomy 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- 230000000242 pagocytic effect Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 239000012980 RPMI-1640 medium Substances 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 229960000448 lactic acid Drugs 0.000 description 7
- 235000014655 lactic acid Nutrition 0.000 description 7
- 239000004310 lactic acid Substances 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 101710088194 Dehydrogenase Proteins 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 5
- 206010057249 Phagocytosis Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- JORABGDXCIBAFL-UHFFFAOYSA-M iodonitrotetrazolium chloride Chemical compound [Cl-].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C=CC=CC=2)=N1 JORABGDXCIBAFL-UHFFFAOYSA-M 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 229950006238 nadide Drugs 0.000 description 5
- 230000008782 phagocytosis Effects 0.000 description 5
- 210000003371 toe Anatomy 0.000 description 5
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- 230000002519 immonomodulatory effect Effects 0.000 description 4
- 230000004957 immunoregulator effect Effects 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 108010006464 Hemolysin Proteins Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003228 hemolysin Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000001539 phagocyte Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- MCPIIUKZBQXOSD-UHFFFAOYSA-N 2-hydroxypropanoic acid;lithium Chemical compound [Li].CC(O)C(O)=O MCPIIUKZBQXOSD-UHFFFAOYSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 244000061458 Solanum melongena Species 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- YHVQIDWAIRCSOQ-UHFFFAOYSA-N 1-nitrotetrazol-2-ium chloride Chemical compound [Cl-].[O-][N+](=O)N1C=[NH+]N=N1 YHVQIDWAIRCSOQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- RXGJTUSBYWCRBK-UHFFFAOYSA-M 5-methylphenazinium methyl sulfate Chemical compound COS([O-])(=O)=O.C1=CC=C2[N+](C)=C(C=CC=C3)C3=NC2=C1 RXGJTUSBYWCRBK-UHFFFAOYSA-M 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940118852 bifidobacterium animalis Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 235000021581 juice product Nutrition 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Inorganic materials [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides Bifidobacterium longum (Bifidobacterium longum), which is characterized in that the preservation number of the Bifidobacterium longum is CGMCC No. 6283. The invention also provides a functional food composition and a preparation method thereof, wherein the method comprises the following steps: the cells of Bifidobacterium longum provided by the present invention are added to food. The invention also provides application of the bifidobacterium longum in preparing a functional food composition with an immunoregulation effect. The bifidobacterium longum provided by the invention has good immunoregulation effect.
Description
Technical field
The present invention relates to a kind of bifidobacterium longum (Bifidobacterium longum) and application thereof and merit
Energy food compositions and preparation method thereof, in particular it relates to a kind of bifidobacterium longum, containing this long bifid
Functional food composition of bacillus and preparation method thereof, and this bifidobacterium longum preparation have immunity tune
Application in the functional food of joint effect.
Background technology
Immunity is a kind of physiological function of human body, relates to nonspecific immunity and specific immunity, non-specific
Property immunity need not contact in advance antigen, and once pathogen enters body, then can quickly remove pathogen.
Phagocyte and natural killer cell all have the effect removed and kill, and are in non-specific immune systems
Important member.Specific immunity has and identifies alien material have exempting from of immunological memory ability specifically
Epidemic disease cell T lymphocyte and bone-marrow-derived lymphocyte.Information Conduction the most primary between immune system is just
It it is cytokine.Every kind of cytokine has different stimulatory functions to different cell types, and they lead to
Cross and combine the specific receptor of cell surface and the growth promoter of inducing cell and functional activity.Human body relies on
This identification of function " oneself " and " non-own " composition, thus destroy and repel the antigen thing entering human body
Matter, or human body itself produced damaging cells and tumor cell etc., to maintain the health of human body.Opposing
Or prevent microorganism or parasitic infection or other undesirable biological intrusion.
Bacillus bifidus, as the advantage physiology bacterium of human intestine, has played important work safeguarding in host health
Can be played body by thalline and component such as integrated peptidoglycan thereof, DNA with, bacillus bifidus
Immunological enhancement function.Bifidobacterium strain has been demonstrated have powerful anti-inflammatory feature, it is possible to carefully
Unbalance being adjusted of intracellular cytokine secretion is repaired；Thin also by dendritic cell and vivo immuning system
Born of the same parents' level affects, and plays humoral immunization and antibody secreted regulation effect.Bacillus bifidus safety is relatively
Height, isolated and purified low cost, the prospect as immunomodulating product will be the most wide.
Summary of the invention
It is an object of the invention to provide a kind of bifidobacterium longum with immunoloregulation function.
To achieve these goals, on the one hand, the invention provides a kind of bifidobacterium longum
(Bifidobacterium longum), wherein, the deposit number of described bifidobacterium longum is CGMCC No.
6283。
Second aspect, the invention provides a kind of method preparing functional food composition, wherein, the party
Method includes: the thalline of the bifidobacterium longum present invention provided adds in food.
The third aspect, the invention provides the combination of a kind of functional food prepared by method as above
Thing.
Fourth aspect, the invention provides bifidobacterium longum as above and has immunomodulating work in preparation
Functional food composition in application.
The bifidobacterium longum that the present invention provides has good immunoregulatory effect.
Other features and advantages of the present invention will be described in detail in detailed description of the invention part subsequently.
Biological deposits
The bifidobacterium longum (Bifidobacterium longum) of the present invention, on June 25th, 2012
It is deposited in (address: court of Beijing, China Committee for Culture Collection of Microorganisms's common micro-organisms center
North Star West Road 1 institute of sun district 3, Institute of Microorganism, Academia Sinica, postcode: 100101)
(depositary institution is abbreviated as CGMCC), deposit number is CGMCC No.6283.
Detailed description of the invention
Hereinafter the detailed description of the invention of the present invention is described in detail.It should be appreciated that this place is retouched
The detailed description of the invention stated is merely to illustrate and explains the present invention, is not limited to the present invention.
On the one hand, the invention provides a kind of bifidobacterium longum (Bifidobacterium longum), wherein,
The deposit number of this bifidobacterium longum is CGMCC No.6283.
The bifidobacterium longum of the present invention is isolatable from the feces of Bama County of Guangxi long lived elder.
The bifidobacterium longum that the present invention provides can produce the viable bacteria body of a large amount of bifidobacterium longum through cultivating,
The not particularly requirement of the method for described cultivation, as long as described bifidobacterium longum can be made to breed, example
As can be according to 107The inoculum concentration of CFU/mL by the inoculation of described bifidobacterium longum in bacillus bifidus
In culture medium, and under anaerobic, after cultivating 8-72 hour at a temperature of 15-38 DEG C, obtain
Culture fluid.The various applicable bacillus bifidus that the culture medium of described bacillus bifidus can be known in the art is cultivated
Culture medium, can be such as milk and/or " lactic acid bacteria biological basis and application " (Yang Jiebin,
Light industry publishing house, 1996 publish) described in lactic acid bacteria (MRS) culture medium.
The present invention can separate the viable bacteria body of the bifidobacterium longum in above-mentioned culture fluid, described separation further
Method have no particular limits, as long as thalline can be enriched with from culture fluid, such as, can pass through
Method that is centrifugal and/or that filter realizes, and described centrifugal and described filtration condition can be known condition,
The present invention does not repeats them here.
Second aspect, the invention provides a kind of method preparing functional food composition, wherein, the party
Method includes: the thalline of the bifidobacterium longum present invention provided adds in food.
The present inventor finds under study for action, either the viable bacteria body of bifidobacterium longum or long bifid
The dead thalline of bacillus, or the mixing thalline of the viable bacteria body of bifidobacterium longum and dead thalline is respectively provided with good
Immunoregulation effect, the method preparing functional food composition therefore provided includes bifidobacterium longum
Viable bacteria body and/or dead thalline add in food.Preferably, in order to further enhance bacillus bifidus to body
Immunoregulation effect, the viable bacteria body of bifidobacterium longum is added in food.
According to the present invention, the preparation method of the dead thalline of described bifidobacterium longum has no particular limits, example
As, the viable bacteria body of the bifidobacterium longum after above-mentioned cultivation can be added Thermal killed, it is also possible to radiated cause
Extremely, it is also possible to be exposed in oxygen lethal.The described condition adding Thermal killed may include that temperature is
65-85 DEG C, the time is 0.5-1.5h.
According to the present invention, although adding in food by the thalline of bifidobacterium longum, the present invention can be realized
Purpose, i.e. play immunoregulatory effect, but under preferable case, with the gross weight of functional food composition
On the basis of amount, the addition of the thalline of described bifidobacterium longum is 102-1011CFU/g, is preferably
106-109CFU/g.Under above-mentioned preferable case, the immunoregulation effect of functional food composition is more notable.
CFU(Colony-Forming Units, colony-forming units) refer to viable bacteria number.Cultivate viable bacteria
During counting, by single thalline or assemble pockets of multiple thalline cultured on solid medium breeding formed
Colony, referred to as colony-forming units, with its express viable bacteria quantity.In the present invention, when cheese milk bar
When the concentration of the dead thalline of bacterium represents with CFU/g, refer to obtain phase by lethal for the viable bacteria body of lactobacillus casei
Answer the dead thalline of quantity, and be dissolved in buffer being configured to desired concn.
In the present invention, food can be any type of food, such as juice product, milk product, bean system
Product etc..Food can also be different according to the difference of edible object.In described functional food composition
Can also containing conventional additive, such as spice, mineral, vitamin, stabilizer, thickening agent,
Preservative etc..
The third aspect, the invention provides the combination of a kind of functional food prepared by method as above
Thing.
The functional food composition meeting above-mentioned requirements can include culture fluid (the such as warp of bifidobacterium longum
The fermented dairy product that the fermentation of this bifidobacterium longum prepares), the viable bacteria body etc. of bifidobacterium longum that separates.
In the present invention, functional food composition is possibly together with food, and food is not as it was previously stated, repeat them here.
Fourth aspect, the invention provides bifidobacterium longum as above and has immunomodulating work in preparation
Functional food composition in application.
The present invention is further illustrated for below example, but and is not so limited the present invention.
In following preparation example, embodiment and comparative example:
Laboratory animal: Balb/c female mice, 6-8 week old, weight 18-22g, SPF level, it is purchased from
Beijing Vital River Experimental Animals Technology Co., Ltd..
Experimental strain: bifidobacterium longum A is that (this bacterial strain was in 2012 6 for the bifidobacterium longum of the present invention
The moon within 25th, be deposited in China Committee for Culture Collection of Microorganisms's common micro-organisms center (address:
Yard 1, BeiChen xi Road, Chaoyang District, Beijing City 3, Institute of Microorganism, Academia Sinica, postcode:
100101) (depositary institution is abbreviated as CGMCC), deposit number is CGMCC No.6283)；
Positive strain (Bifidobacterium animalis ssp.Lactis BB12, animal bifid BB12) is purchased from
Chr.Hansen company of Denmark.
Experiment reagent: ConA, Giemsa dyestuff, is purchased from Sigma company；TritonX (Triton
X-100), purchased from Merck company；Hyclone (FBS), purchased from PAA company；MTT, purchases
From Promega company；Sheep red blood cell (SRBC) (SRBC), purchased from Department Of Medicine, Peking University's animal center；
Chicken red blood cell (CRBC), purchased from animal medicine institute of China Agricultural University；K562 cell, purchased from China
Academy of Medical Sciences Institute of Basic Medical Sciences cell centre；Guinea pig serum, Dou Shi reagent, be purchased from middle traditional Chinese medical science
Institute of Medical Plants of subject institute；Skimmed milk, purchased from Mengniu (group) limited company；
Hank ' s liquid, purchased from Hyclone company.
Lactic acid dehydrogenase (LDH) matrix liquid: containing DL-LACTIC ACID lithium 5 × 10-2Mol/L, INT(nitro
Tetrazolium chloride) 6.6 × 10-4Mol/L, PMS(phenazine methosulfate) 2.8 × 10-4mol/L, NAD(oxygen
Change type cozymase) 1.3 × 10-3mol/L, it is dissolved in Tris-HCL(0.2mol/L, pH8.2), need to now use
Now join.Wherein, PMS and INT is purchased from Amresco company；NAD is purchased from Roche company；DL-
EINECS 212-761-8 is purchased from Merck company.
Cell pyrolysis liquid: purchased from company difficult to understand of section hundred
The incomplete culture medium of RPMI-1640: the RPMI-1640 culture medium dry powder (Gibco of 2 weight %
Company), 100IU/mL penicillin (Amresco company), 100mg/mL streptomycin (Amresco
Company).
RPMI-1640 complete medium: added 10 volumes by the incomplete culture medium of RPMI-1640
% hyclone (Hyclone company) is formulated.
NPNL culture medium (neomycin-paromomycin-nalidixic acid-lithium chloride):
Peptone 10g, Carnis Bovis seu Bubali cream 3g, yeast leaching powder 5g, glucose 10g, tryptone 5g, soybean protein
Peptone 3g, Hepar Bovis seu Bubali powder 10g, soluble starch 0.5g, cysteine hydrochloride 0.5g, Tween 80 1g,
Buffer A (K2HPO425g, KH2PO425g, H2O250ml) 10ml, buffer B
(MgSO4·7H2O0.5g, FeSO4·7H2O0.5g, NaCl0.5g, MnSO40.337g, H2O
250ml) 5ml, distilled water 1000ml, adjust pH to 7.2.Solid medium adds the fine jade of 1.5 weight %
Cosmetics.121 DEG C, 15min, sterilizing is standby.
Experimental apparatus: slide gauge, Mitutoyo company；UV-2102 ultraviolet spectrophotometer, UNICO
Company；Bio-rad Model680 microplate reader, Bio-rad company of the U.S.；MCO-15AC type CO2Training
Support case, SANYO company；High-pressure sterilizing pot, model is ZDX35BI, pacifies Medical treatment device purchased from Shen, Shanghai
Tool factory；Constant incubator, model is DNP9082, purchased from upper Nereid grand experimental facilities company limited；Low
Temperature high speed centrifuge, model be 3K30: model be ACCULAB, purchased from Germany Satorious company.
Preparation example
(1) preparation of bifidobacterium longum A viable bacteria body bacteria suspension: by bifidobacterium longum A with 1 volume %
Inoculum concentration in liquid NPNL culture medium in constant incubator 37 DEG C of Anaerobic culturel 14h, make bacterium dense
Degree reaches 109CFU/ml, bacterium solution is at room temperature centrifuged 10 minutes with 4000g and collects thalline, and thalline is used
Physiological saline solution is resuspended wash twice after, with 12%(w/v) sterile absorbent breast adjust thalline, point
It is not configured to 2 × 102The bacteria suspension B1 of CFU/ml, 2 × 104The bacteria suspension B2 of CFU/mL,
2×106The bacteria suspension B3 of CFU/ml, 2 × 107The bacteria suspension B4 of CFU/ml, 2 × 108The bacterium of CFU/ml
Suspension B5,2 × 109The bacteria suspension B6 of CFU/ml, 2 × 1010The bacteria suspension B7 of CFU/ml and
2×1011The bacteria suspension B8 of CFU/ml.
(2) preparation of bifidobacterium longum A dead thalline bacteria suspension: take in part above-mentioned (1) and cultivate to right
The bacillus bifidus A of number phase, 70 DEG C inactivate 1 hour, and 4000g is centrifuged 10 minutes and collects thalline, with 12%
(w/v) sterile absorbent breast adjusts thalline, is configured to 2 × 108The bacteria suspension B9 of CFU/ml.
(3) bifidobacterium longum A mixes the preparation of thalline bacteria suspension anyway: according in (3) and (4)
Method prepare the viable bacteria body of bifidobacterium longum and dead thalline, and be configured to according to the mass ratio of 1:1
2×108The bacteria suspension B10 of CFU/ml.
(4) 2 × 10 are prepared according to the method for (1)8The bacteria suspension B11 of CFU/ml animal bifid BB12.
(5) mice is randomly divided into 12 groups, often group 10, room temperature 22 ± 2 DEG C, 12 hours lamps according to/black
Dark circulation, freely drinks water and ingests, and adaptability is standby after raising 5 days.
Embodiment 1-10
For the immunoregulation effect of bifidobacterium longum A that the present invention provides is described
(1) take 10 groups of mices in preparation example (5), the most disposably gavage 0.2mL bacterium every day and hang
Liquid B1, bacteria suspension B2, bacteria suspension B3, bacteria suspension B4, bacteria suspension B5, bacteria suspension B6, bacterium are hanged
Liquid B7, bacteria suspension B8, bacteria suspension B9 and bacteria suspension B10.Gavage 4 weeks continuously.
(2) delayed hypersensitivity (DTH) of SRBC induction
Delayed hypersensitivity can be produced by inducing mouse after SRBC is injected mouse peritoneal, stimulate T lymph
Cell proliferation becomes primed lymphocyte, and after 4 days, when attacking with SRBC, visible attack portion position can go out again
Existing delayed hypersensitivity, the toes thickness before after again injecting 24 hours of SRBC and again injecting
Difference reacted the power of delayed hypersensitivity.
Gavage after bacteria suspension terminates, inject 0.5mL2%(v/v to each mouse peritoneal) SRBC sensitization.
After 4 days, with vernier caliper measurement left back toes thickness, the subcutaneous injection 20%(v/v in measuring point)
SRBC, every 20 μ L, again measure left back toes portion thickness after 24 hours, same position is repeated
Measure and average for 3 times.The extent of reaction of DTH is represented with the toes thickness difference before and after attacking,
The results are shown in Table 1.
(3) half hemolytic dose (HC50)
SRBC can stimulate B cell proliferation as a kind of antigen and be divided into plasma cell, and plasma cell is at lymph
Through 3-4 days maturations in knot or lymphoid tissue, the antibody hemolysin corresponding with SRBC can be secreted,
And be discharged in body fluid, the content of the hemolysin in mensuration mice body fluid, objectively it is able to demonstrate that reflection is little
The specific humoral immunity function of Mus.
Gavaging before the mice after bacteria suspension terminates slaughters by above-mentioned, extracing eyeball and take blood, blood sample
At room temperature place blood coagulation in 3 hours, be subsequently placed in 4 DEG C of refrigerators 12 hours, more at room temperature 1000rpm
Centrifugal 10 minutes, collecting upper serum, if being mixed with erythrocyte, then recentrifuge, drawing supernatant.Blood
The mensuration of clear hemolysin is according to health food inspection and assessment technique specification (People's Republic of China's health
Portion, 2003) carry out.The blood serum sample normal saline dilution 500 times of 0.9 weight %, guinea pig serum
With normal saline dilution 10 times.The blood serum sample of every milliliter of dilution adds 0.5mL10%SRBC(v/v),
And 1mL guinea pig serum.Blank normal saline replaces mice serum.By above system 37
DEG C hatching 30 minutes, sample is centrifuged 10 minutes with 2000g at 4 DEG C, to remove the reddest of non-haemolysis
Cell precipitates.Collect supernatant, mix with the ratio of 1:3 with reaction terminating liquid (Dou Shi reagent), use
Ultraviolet spectrophotometer measures optical density value under 540nm, with OD540nmRepresent haemolysis in mice serum
The content of element, wherein, the OD of test sample540nmValue is the OD relative to the comparison of this step empty540nm
Value, the results are shown in Table 1.
(4) drip sheet method and measure the phagocytic rate of macrophage phagocytic chicken red blood cell (CRBC)
When, after allosome material chicken red blood cell (CRBC) intrusion system, macrophage can be known by assembling
Not and swallow three steps of elimination it is completed phagocytosis.
After mice excision eyeball takes blood, put to death through cervical dislocation.Abdominal part is carefully cut off in superclean bench
Fur, exposes peritoneum, contains 5%(v/v with asepsis injector to lumbar injection 4mL) hyclone
Hank ' s liquid.Rub gently abdominal part several under, with syringe sucking-off abdominal cavity liquid (about 2ml), Qi Zhonghan
There is macrophage.The activity of macrophage phagocytic CRBCs uses Giemsa flat board Determination Staining
(Ghoneum M, 2004) (main agents related in the method has: Giemsa dyestuff), uses optics
The CRBC number of microscopic counting phagocytosis.The phagocytic activity of macrophage is with counting quilt under 60 times of light microscopics
The CRBC number of phagocytosis represents.Every slide 100 macrophages of counting, phagocytic rate is every 100
Macrophage swallows the percentage ratio shared by the macrophage of CRBC.The results are shown in Table 1.
(5) lactic acid dehydrogenase (LDH) method measures natural killer cell (NK cell) activity
The endochylema of living cells includes lactic acid dehydrogenase (LDH).Under normal circumstances, LDH can not be through thin
After birth, after cell is by the killing of NK cell, LDH is discharged into extracellular.LDH can make lactic acid
Lithium dehydrogenation, and then make oxidized coenzyme I (NAD) be reduced into reduced coenzyme Ⅰ (NADH), after
Person is again through hydrogen carrier PMS(PMS) reduction INT(p-Iodonitrotetrazolium violet),
INT accepts H+It is reduced into aubergine compound.By colorimetric method for determining end-product aubergine compound
Content, it is possible to the cell concentration that killed of reflection, and then the killing activity of reflection natural killer cell.
Aseptic taking-up mouse spleen, is placed on 200 mesh metallic sieves, and screen cloth is immersed in containing RPMI-1640
Not exclusively in the culture dish of culture medium.It is lightly ground spleen tissue so that it is by 200 with glass syringe inner core
Eye mesh screen, obtains monokaryon splenocyte.Splenocyte liquid is transferred to centrifuge tube, adds sterilized water and gently shakes 20 seconds
To crack erythrocyte therein, add 2 × hank ' s liquid immediately and recover stock solution pressure.(spleen drenches remaining cell
Bar cell) wash twice by the incomplete culture medium of RPMI-1640, it is resuspended in RPMI-1640 and trains completely
Supporting in base, adjusting cell concentration is 2 × 107Individual/ml.Disclosed in (Trzonkowski P, 2004)
Colorimetry use microplate reader to measure activity (the main examination related in the method for LDH under 490nm
Agent has: LDH matrix liquid), thin as target using man-machine systems K562 cell cell sensitive to NK
Born of the same parents, represent, by the activity of the LDH discharged in the target cell solute killed, the cell concentration killed,
The results are shown in Table 1.Natural killer cell activity is calculated by below equation:
Killing rate (%)=(test hole OD490-Spontaneous release hole OD490)/(maximum release aperture OD490-
Spontaneous release hole OD490) × 100.
Wherein, test hole OD490Represent that target cell is measured by the killing of the splenocyte of the present invention, Spontaneous release
Hole OD490Represent target cell killing amount in its natural state, maximum release aperture OD490Represent target cell
Killing amount completely.
(6) propagation of splenocyte
Use the increasing measuring splenocyte according to the mtt assay disclosed in (Bujalance C, 2007)
Grow (main agents related in the method has ConA, Triton X-100).By microplate reader at 570nm
The light absorption value in the lower each hole of mensuration, the Spleen cell proliferation situation rate of increase represents, calculates by equation below, knot
Fruit is shown in Table 1.
The rate of increase=(stimulate hole OD570-control wells OD570)/control wells OD570× 100%, wherein,
Stimulating hole is the culture hole using ConA to stimulate splenocyte, and control wells is not for use ConA to stimulate
The culture hole of splenocyte.
Comparative example 1
This comparative example is for illustrating the immunoregulation effect of positive control strain
Feed laboratory animal according to the method in embodiment 1-10, the delayed of SRBC induction becomes
The state reaction mensuration of (DTH), the mensuration of half hemolytic dose (HC50), a sheet method measure huge
The mensuration of phagocytic rate of phagocyte phagocytosis chicken red blood cell (CRBC), lactic acid dehydrogenase (LDH) method are surveyed
Determine the mensuration of natural killer cell (NK cell) activity and the mensuration of the propagation of splenocyte, no
With, to laboratory animal gavage for bacteria suspension B11.Test result is shown in Table 1.
Comparative example 2
This comparative example is for illustrating the immunoregulation effect of mice self under naturalness
Feed laboratory animal according to the method in embodiment 1-10, the delayed of SRBC induction becomes
The state reaction mensuration of (DTH), the mensuration of half hemolytic dose (HC50), a sheet method measure huge
The mensuration of phagocytic rate of phagocyte phagocytosis chicken red blood cell (CRBC), lactic acid dehydrogenase (LDH) method are surveyed
Determine the mensuration of natural killer cell (NK cell) activity and the mensuration of the propagation of splenocyte, no
With, to laboratory animal gavage for isodose 12%(w/v) skimmed milk.Test result is shown in
Table 1.
Table 1
By upper table 1 it can be seen that embodiment 1-10 is compared with comparative example 2 respectively it can be seen that
The bifidobacterium longum (viable bacteria body, dead thalline, the mixing thalline of dead thalline of living) using the present invention feeds little
Mus, and by the test of each immune performance, the toes thickness of mice, half hemolytic dose, huge bite thin
Born of the same parents' phagocytic rate, NK cell killing rate and lymphocytic proliferation rate all have the increase of significance, and this is described
The bifidobacterium longum of invention has immunoregulatory effect.By embodiment 3-6 respectively with embodiment 1 and real
Execute example 2 and embodiment 7 and embodiment 8 compares it can be seen that with the gross weight of mixture as base
Standard, the addition of bacillus bifidus is 106-109During CFU/ml, brighter to the immunoregulation effect of body
Aobvious；By embodiment 5 respectively with embodiment 9 and embodiment 10 compares it can be seen that bacillus bifidus
Viable bacteria body the immunoregulation effect of body is become apparent from.
Embodiment 5 and comparative example 1 are compared it can be seen that the bifidobacterium longum of the present invention is to body
Immunoregulation effect be better than the commercial strain animal bifid BB12 immunoregulation effect to body.
In sum, the thalline after the viable bacteria body of the bifidobacterium longum that the present invention provides, inactivation and viable bacteria
The mixing thalline of body and dead thalline is respectively provided with immunoregulatory effect.
The preferred embodiment of the present invention described in detail above, but, the present invention is not limited to above-mentioned reality
Execute the detail in mode, in the technology concept of the present invention, can be to the technical side of the present invention
Case carries out multiple simple variant, and these simple variant belong to protection scope of the present invention.
It is further to note that each the concrete technology described in above-mentioned detailed description of the invention is special
Levy, in the case of reconcilable, can be combined by any suitable means, in order to avoid need not
The repetition wanted, various possible compound modes are illustrated by the present invention the most separately.
Additionally, combination in any can also be carried out between the various different embodiment of the present invention, as long as its
Without prejudice to the thought of the present invention, it should be considered as content disclosed in this invention equally.
Claims (8)
1. a bifidobacterium longum (Bifidobacterium longum), it is characterised in that described length is double
The deposit number of discrimination bacillus is CGMCC No.6283.
2. the method preparing functional food composition, it is characterised in that the method includes: will power
Profit requires that the thalline of the bifidobacterium longum described in 1 adds in food.
Method the most according to claim 2, wherein, the thalline of described bifidobacterium longum is for long double
The viable bacteria body of discrimination bacillus and/or dead thalline.
Method the most according to claim 3, wherein, the thalline of described bifidobacterium longum is for long double
The viable bacteria body of discrimination bacillus.
5. according to the method described in any one in claim 2-4, wherein, with described functional food
On the basis of the gross weight of compositions, the addition of the thalline of described bifidobacterium longum is 102-1011CFU/g。
Method the most according to claim 5, wherein, with the gross weight of described functional food composition
On the basis of amount, the addition of the thalline of described bifidobacterium longum is 106-109CFU/g。
7. the functional food composition prepared by the method described in any one in claim 2-6.
8. the bifidobacterium longum described in claim 1 has the functional food of immunoregulation effect in preparation
Application in compositions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310149307.3A CN104120093B (en) | 2013-04-26 | 2013-04-26 | Bifidobacterium longum and application thereof, and functional food composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310149307.3A CN104120093B (en) | 2013-04-26 | 2013-04-26 | Bifidobacterium longum and application thereof, and functional food composition and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104120093A CN104120093A (en) | 2014-10-29 |
| CN104120093B true CN104120093B (en) | 2016-12-28 |
Family
ID=51765724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310149307.3A Active CN104120093B (en) | 2013-04-26 | 2013-04-26 | Bifidobacterium longum and application thereof, and functional food composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104120093B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105796606A (en) * | 2014-12-29 | 2016-07-27 | 广州海思医疗科技有限公司 | Probiotics composition for reducing risk of fetal congenital heart disease and detecting method thereof |
| CN107893044B (en) * | 2017-12-27 | 2019-11-08 | 江南大学 | One plant of bifidobacterium longum and its application |
| CN116042427A (en) * | 2021-10-28 | 2023-05-02 | 南京盛德生物科技研究院有限公司 | Bifidobacterium longum, screening method thereof and preparation method of lysate of fermentation product of saccharomyces cerevisiae |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101649303A (en) * | 2009-05-08 | 2010-02-17 | 内蒙古蒙牛乳业（集团）股份有限公司 | Bifidobacterium, application thereof and food composition containing same |
| CN102018216A (en) * | 2009-09-19 | 2011-04-20 | 菲伯纳生物医药有限责任公司 | Composition containing bifidobacteria for adjusting intestinal flora and enhancing immunity |
| CN102869365A (en) * | 2009-05-11 | 2013-01-09 | 雀巢产品技术援助有限公司 | Bifidobacterium longum NCC2705 (CNCM I-2618) and immune disorders |
| CN103002901A (en) * | 2010-06-18 | 2013-03-27 | 雀巢产品技术援助有限公司 | L. johnsonii la1, b. longum ncc2705 and immune disorders |
-
2013
- 2013-04-26 CN CN201310149307.3A patent/CN104120093B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101649303A (en) * | 2009-05-08 | 2010-02-17 | 内蒙古蒙牛乳业（集团）股份有限公司 | Bifidobacterium, application thereof and food composition containing same |
| CN102869365A (en) * | 2009-05-11 | 2013-01-09 | 雀巢产品技术援助有限公司 | Bifidobacterium longum NCC2705 (CNCM I-2618) and immune disorders |
| CN102018216A (en) * | 2009-09-19 | 2011-04-20 | 菲伯纳生物医药有限责任公司 | Composition containing bifidobacteria for adjusting intestinal flora and enhancing immunity |
| CN103002901A (en) * | 2010-06-18 | 2013-03-27 | 雀巢产品技术援助有限公司 | L. johnsonii la1, b. longum ncc2705 and immune disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104120093A (en) | 2014-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102123715B (en) | Immune system stimulating nutrition | |
| CN100552016C (en) | The bifidus bacillus that is used for the treatment of inflammatory diseases | |
| CN105343133B (en) | A kind of compound probiotic that treating ulcerative colitis, drug and preparation method thereof | |
| Yang et al. | Oral administration of live Bifidobacterium substrains isolated from healthy centenarians enhanced immune function in BALB/c mice | |
| JP5868843B2 (en) | Preparation containing lactic acid bacteria | |
| CN101260377B (en) | Animal bifidobacteria and use thereof | |
| CN104523762B (en) | The application of lactobacillus paracasei with anti-allergic effects and functional food composition and preparation method thereof | |
| CN101144062B (en) | Lactobacillus casei strain and application for products thereof in bird immunity | |
| CN101171019A (en) | Immune function modulating agents | |
| CN101649303B (en) | Bifidobacterium, application thereof and food composition containing same | |
| CN104498383B (en) | A kind of lactobacillus fermenti Lactobacillus fermentum strain suo and application thereof of adjustable intestinal movement, Constipation | |
| CN1602199B (en) | Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation | |
| CN104531549B (en) | A kind of lactobacillus fermenti Lactobacillus fermentum strain Zhao and application thereof of adjustable intestinal movement, Constipation | |
| CN104430847B (en) | Lactobacillus fermenti Lactobacillus fermentum Lee working stock cultures products and its Constipation health purpose | |
| CN109666609A (en) | A kind of Rhodococcus ruber fermentation process and its application as adjuvant in animal vaccine | |
| CN104381440B (en) | Lactobacillus fermenti Lactobacillus fermentum strain Lee working stock cultures products and its Constipation health purpose | |
| CN104224851B (en) | The application of bifidobacterium animalis acid subspecies CGMCC No.9273 | |
| CN104120093B (en) | Bifidobacterium longum and application thereof, and functional food composition and preparation method thereof | |
| CN105327338B (en) | A kind of drug and preparation method thereof for treating ulcerative colitis | |
| CN105343132B (en) | Composition, the drug and preparation method thereof for treating colitis | |
| CN104651271A (en) | Lactobacillus casei strain Qian working leavening agent product and intestinal tract regulating health use thereof | |
| CN107213164A (en) | The preparation method of Tiny ecosystem soil compound | |
| CN105725215A (en) | Lactobacillus oral solution and preparation method thereof | |
| Flore et al. | Immune system stimulation in rats by Lactobacillus sp. isolates from Raffia wine (Raphia vinifera) | |
| CN102058884B (en) | Grass carp injection vaccine synergist and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Ren Fazheng Inventor after: Zhao Liang Inventor after: Liu Songling Inventor before: Ren Fazheng |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160825 Address after: 100083 Haidian District Qinghua East Road, No. 17, Beijing Applicant after: China Agricultural University Address before: 100085, room 5, building 39, No. 203 West Road, Beijing, Haidian District Applicant before: Beijing Zhongtian Shenzhou Space Foods Technology Research Institute |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170427 Address after: 851400 A in Tibet District of Lhasa economic and Technological Development Zone Qionggang Lin Road East Road No. 6 Patentee after: TIBET TREASURE OF PLATEAU YAK DAIRY INDUSTRY CO., LTD. Address before: 100083 Haidian District Qinghua East Road, No. 17, Beijing Patentee before: China Agricultural University |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211014 Address after: 851400 No. 6, East 1st Road, linqionggang Road, zone a, Lhasa Economic and Technological Development Zone, Lhasa City, Tibet Autonomous Region Patentee after: TIBET TREASURE OF PLATEAU YAK DAIRY INDUSTRY Co.,Ltd. Patentee after: QINGHAI TREASURE OF PLATEAU YAK MILK Co.,Ltd. Patentee after: RUOERBAO TREASURE OF PLATEAU YAK MILK Co.,Ltd. Address before: 851400 No.6, East 1st Road, linqionggang Road, zone a, Lhasa Economic and Technological Development Zone, Tibet Patentee before: TIBET TREASURE OF PLATEAU YAK DAIRY INDUSTRY Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 851400 No. 6, East 1st Road, linqionggang Road, zone a, Lhasa Economic and Technological Development Zone, Lhasa City, Tibet Autonomous Region Patentee after: TIBET TREASURE OF PLATEAU YAK DAIRY INDUSTRY Co.,Ltd. Patentee after: QINGHAI TREASURE OF PLATEAU YAK MILK CO.,LTD. Patentee after: Ruoergai Plateau Zhibao yak milk nutritional food Co.,Ltd. Address before: 851400 No. 6, East 1st Road, linqionggang Road, zone a, Lhasa Economic and Technological Development Zone, Lhasa City, Tibet Autonomous Region Patentee before: TIBET TREASURE OF PLATEAU YAK DAIRY INDUSTRY Co.,Ltd. Patentee before: QINGHAI TREASURE OF PLATEAU YAK MILK CO.,LTD. Patentee before: RUOERBAO TREASURE OF PLATEAU YAK MILK CO.,LTD. |
|
| CP01 | Change in the name or title of a patent holder |